Paratek Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$133M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Paratek Pharmaceuticals's estimated annual revenue is currently $17.1M per year.(i)
  • Paratek Pharmaceuticals received $50.0M in venture funding in January 2018.
  • Paratek Pharmaceuticals's estimated revenue per employee is $71,920
  • Paratek Pharmaceuticals's total funding is $133M.

Employee Data

  • Paratek Pharmaceuticals has 238 Employees.(i)
  • Paratek Pharmaceuticals grew their employee count by 5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M347-5%$634MN/A
#2
$50.9M253N/AN/AN/A
#3
$39.6M197-12%N/AN/A
#4
$11.6M2140%$506.4MN/A
#5
$4360M37257175%N/AN/A
#6
$16.3M81N/AN/AN/A
#7
$37.2M185N/AN/AN/A
#8
$3.2M16N/AN/AN/A
#9
$5.6M28-3%N/AN/A
#10
$888.2M44190%N/AN/A

Paratek Pharmaceuticals (NASDAQ: PRTK) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. We focus on drugs that target infectious disease and other difficult to treat conditions. Our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. The Food and Drug Administration (FDA) granted omadacycline a Qualified Infectious Disease Product (QIDP) designation and completed two special protocol assessments for its Phase 3 clinical trial program.

keywords:Biotechnology,Healthcare,Mobile,Pharmaceuticals

$133M

Total Funding

238

Number of Employees

$17.1M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Paratek Pharmaceuticals News

2021-06-01 - PARATEK PHARMACEUTICALS, INC. Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

- Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion - Primary Care Market Opportunity for CABP Estimated at Approximately $1.5 Billion BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-sta ...

2007-10-25 - Life sciences briefing: Thursday, Oct. 25, 2007

Featured companies: BioVex, Cavadis, Innovention, Paratek Pharmaceuticals, Phase Bioscience, Reliant Pharmaceuticals, Xencor UPDATED: Expanded Paratek and Xencor items. Paratek Pharma raises $40M for new antibiotics — Boston’s Paratek Pharmaceuticals, a biotech working on new antibiotics to tr ...

09/07/2019 - Paratek Pharmaceuticals to Present at the 21st Annual HC ...

BOSTON, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company ...

09/08/2019 - Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Buckles ...

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) stock has been on a recent steady downtrend, causing some concern for shareholders.

09/03/2019 - Paratek Announces Inducement Grants under NASDAQ ...

BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$38M23814%N/A
#2
$62.7M238-4%$21M
#3
$65.7M23914%N/A
#4
$83.5M23912%$13.3M
#5
$37.3M239285%$132M

Paratek Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2002-04-11$30.2MDArticle
2004-10-01$13.7MUndisclosedBayerArticle
2007-10-26$22.0MHArticle
2008-04-17$40.0MUndisclosedAisling Capital, D.E. Shaw GroupArticle
2014-07-21$93.0MUndisclosedArticle
2015-04-29$69.0MUndisclosedLeerink PartnersArticle
2018-01-19$50.0MUndisclosedBTIG, LLCArticle